Skip to main content

Sequenom Shares Climb 11 Percent, then Fall 13 Percent on News of CEO Schuh s Resignation

This update inlcudes share price information.

 

NEW YORK, Feb. 9 (GenomeWeb News) - Shares in Sequenom plunged 12.87 percent, or $.22, to $1.49 in mid-afternoon trading shares after the company said CEO Toni Schuh has resigned.

 

The shares closed up 11 percent at $1.71 after the company made the abrupt announcement last night, but the gains were quickly erased in overnight and early-morning trading today.

 

As GenomeWeb News reported this morning, Schuh has resigned as CEO of the company and as a director, according to a terse statement Sequenom issued last night. Steve Zaniboni, Sequenom's chief financial officer, will take over Schuh's position while the company looks for a permanent replacement, Sequenom said.

 

Schuh will remain as a consultant to Sequenom for up to 12 months, the company said.

 

According to  Pharmacogenomics Reporter, a GenomeWeb News publication, Schuh has been under pressure from his board to revive the high-throughout genotyping company after a fling with drug discovery hurt revenue growth and investor confidence, and  nearly cost the company its position on the Nasdaq exchange.

 

Since abandoning its drug-discovery business in August, Sequenom has turned its attention toward selling its flagship MassArray genotyping platform -- which has lagged behind rival instruments -- and has signed on new customers. The San Diego-based company is also attempting to grow its presence in the molecular diagnostics industry, and its share price has also rebounded.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.